Key points from article :
Jeune Aesthetics plans on initiating a Phase 2 trial in fine lines and wrinkles in 1H 2023.
Up to nine months durability of effect observed in patients aged 55 to 76 in the extension cohort following administration of high dose KB301.
Phase 1 trial included non-integrating HSV-1 vector expressing human type III collagen (COL3) injection.
"Treatment of superficial fine lines has been a challenge and as one of the first signs of skin aging, fine lines.
Replenishment of the skin’s key proteins through targeted gene-delivery holds promise for this significant market segment.
We look forward to including a younger patient population in our future Phase 2 study," said September Riharb, SVP of Jeune.
The Phase 2 study will be a multicenter, randomized, double-blind, placebo-controlled study to assess improvement of fine lines and wrinkles in challenging areas of the face.
